Advertisement
IQV vs TMO
Which Stock Would AI Choose? IQVIA Holdings Inc. (IQV) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- IQV has delivered stronger year-to-date gains of approximately 30%, outpacing TMO's 19% rise, reflecting robust momentum in clinical research services.
- TMO maintains a significantly larger market capitalization of over $174 billion compared to IQV's $26 billion, underscoring its scale in scientific instruments and lab products.
- Both stocks operate in the life sciences sector but diverge in focus: IQV emphasizes data analytics and clinical trials, while TMO leads in analytical tools and biopharma services.
- Recent catalysts include IQV's AI advancements with NVIDIA and TMO's Q1 earnings beat with 6% revenue growth and strategic expansions.
- TMO provides a modest dividend yield of about 0.38%, appealing to income-focused investors, whereas IQV reinvests for growth.
- Tickeron's AI tools highlight opportunities in volatile healthcare stocks through pattern-based trading strategies.
Introduction
IQV and TMO represent key players in the life sciences sector, where demand for healthcare innovation drives investment interest. IQVIA Holdings Inc. specializes in advanced analytics, technology solutions, and clinical research services, while Thermo Fisher Scientific Inc. excels in scientific instruments, diagnostics, and laboratory products. This stock comparison is particularly relevant for traders seeking growth opportunities in data-driven healthcare and investors prioritizing stable, diversified exposure to biopharma tools amid market volatility. By examining recent performance, business models, and market positioning, readers can assess relative strengths for portfolio allocation in the evolving healthcare landscape.
IQV Overview and Recent Performance
IQVIA Holdings Inc. (IQV) is a global leader in providing advanced analytics, technology solutions, and clinical research services to the life sciences industry, operating through segments like Technology & Analytics Solutions and Research & Development Solutions. In recent market activity, IQV shares have demonstrated strong resilience, advancing roughly 30% year-to-date despite broader sector pressures. This momentum follows solid Q4 2025 results with revenue growth exceeding 10%, though tempered by initial concerns over full-year guidance. Key influences include the launch of IQVIA.ai in partnership with NVIDIA, spotlighting AI-driven valuation potential, and anticipation for upcoming quarterly results. Sentiment has shifted positively on analytics demand, with the stock trading around $158 amid a 52-week range of $135 to $247, supported by a P/E ratio (price-to-earnings ratio) of about 20.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) delivers life sciences solutions, analytical instruments, specialty diagnostics, and biopharma services worldwide, structured across segments such as Life Sciences Solutions and Laboratory Products. Recent weeks have seen TMO shares gain approximately 19% year-to-date, bolstered by a Q1 2026 earnings report showing 6% revenue growth to $11 billion and adjusted EPS (earnings per share) of $5.44 beating estimates. Developments like the opening of a U.S. bioprocess design center and a $1 billion sale of its microbiology business have enhanced strategic focus, while billionaire investor interest underscores confidence. Trading near $469 within a 52-week range of $385 to $644 and a P/E of around 26, performance reflects steady demand in biopharma amid moderated volatility (beta of 0.88).
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from a library of hundreds that trade thousands of tickers across diverse strategies, timeframes, and market conditions. Featuring 25 standout bots selected from 351 total, it highlights those excelling in current volatility, with annualized returns ranging from +23.53% to +163.10%, win rates of 51.30% to 88.33%, profit factors up to 1.75, and low drawdowns. Examples include semiconductor-focused bots with +83.59% returns and 68% win rates on short timeframes like 5 minutes, or space sector plays yielding +126.82%. These automated systems offer real-time signals, risk management, and customization for styles from swing trading to high-frequency, making them ideal for navigating healthcare stock swings like IQV and TMO. Explore the page to identify bots aligning with your risk profile and market outlook.
Head-to-Head Comparison
IQV and TMO share life sciences exposure but contrast in business models: IQV's service-oriented analytics and trials offer high growth potential tied to R&D (research and development) pipelines, while TMO's product-heavy portfolio provides recurring revenue from instruments and consumables. Growth drivers differ, with IQV benefiting from AI and data demand versus TMO's biopharma tailwinds. Recent momentum favors IQV's YTD surge, but TMO shows one-year outperformance in some metrics. Risk profiles highlight IQV's higher beta (1.18) and debt levels versus TMO's stability and dividend. Market sentiment leans toward TMO for scale amid economic uncertainty, trading off IQV's agility.
Tickeron AI Verdict
Tickeron’s AI currently favors TMO based on its trend consistency through earnings beats, lower volatility, expansive biopharma catalysts like facility openings, and superior scale relative to IQV. While IQV exhibits stronger short-term momentum and AI upside, TMO's positioning suggests higher probability of sustained outperformance in the near term, barring major sector shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IQV is a Hold and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- IQV’s TA Score: 5 bullish, 4 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
IQV (@Medical Specialties) experienced а -1.08% price change this week, while TMO (@Medical Specialties) price change was -0.73% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | TMO | IQV / TMO | |
| Capitalization | 30.3B | 174B | 17% |
| EBITDA | 3.52B | 11.7B | 30% |
| Gain YTD | -19.498 | -18.922 | 103% |
| P/E Ratio | 22.54 | 25.80 | 87% |
| Revenue | 16.6B | 45.2B | 37% |
| Total Cash | 2.1B | 3.26B | 65% |
| Total Debt | 16.1B | 43.2B | 37% |
IQV | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 93 | |
SMR RATING 1..100 | 42 | 62 | |
PRICE GROWTH RATING 1..100 | 51 | 53 | |
P/E GROWTH RATING 1..100 | 49 | 47 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is somewhat better than the same rating for IQV (62) in the Servicestothe Health Industry industry. This means that TMO’s stock grew somewhat faster than IQV’s over the last 12 months.
TMO's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as TMO (62) in the Medical Specialties industry. This means that IQV’s stock grew similarly to TMO’s over the last 12 months.
IQV's Price Growth Rating (51) in the Servicestothe Health Industry industry is in the same range as TMO (53) in the Medical Specialties industry. This means that IQV’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (47) in the Medical Specialties industry is in the same range as IQV (49) in the Servicestothe Health Industry industry. This means that TMO’s stock grew similarly to IQV’s over the last 12 months.
| IQV | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 68% | 3 days ago 57% |
| Momentum ODDS (%) | 3 days ago 66% | 3 days ago 57% |
| MACD ODDS (%) | 3 days ago 63% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 61% |
| Advances ODDS (%) | 6 days ago 58% | 14 days ago 62% |
| Declines ODDS (%) | 4 days ago 65% | 3 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 54% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 51% | 3 days ago 63% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | +0.22% | ||
| CRL - IQV | 75% Closely correlated | -0.29% | ||
| TMO - IQV | 71% Closely correlated | -1.33% | ||
| MEDP - IQV | 69% Closely correlated | -1.63% | ||
| RVTY - IQV | 66% Loosely correlated | -1.83% | ||
| A - IQV | 63% Loosely correlated | +0.22% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.